Evaluation of the dopamine β-hydroxylase (DβH) inhibitor nepicastat in participants who meet criteria for cocaine use disorder

Richard De La Garza, Marcy J. Bubar, Crystal L. Carbone, F. Gerard Moeller, Thomas F. Newton, Noelle Anastasio, Tod A. Harper, David L. Ware, Michael Fuller, Gaylyn J. Holstein, Jason B. Jayroe, Stephen I. Bandak, Kirsten Z. Reiman, Ann C. Neale, Lesley B. Pickford, Kathryn Cunningham

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

In the present study, we tested the hypothesis that the potent and selective dopamine-β-hydroxylase (DβH) inhibitor nepicastat would have minimal effects on cardiovascular and pharmacokinetic parameters associated with cocaine administration and would reduce the positive subjective effects produced by cocaine. We conducted a double-blind, placebo-controlled, inpatient study of oral nepicastat (0, 80 and 160. mg) concurrent with intravenous (IV) cocaine (0, 10, 20 and 40. mg) in non-treatment seeking participants who metcriteria for cocaine use disorder. Safety analyses revealed that nepicastat was well-tolerated and there were no differences in adverse events observed after nepicastat plus cocaine vs. cocaine alone. In addition, the pharmacokinetic properties of cocaine administration were not altered by nepicastat treatment. Cocaine-induced cardiovascular and subjective effects were evaluated for completers in the cohort randomized to nepicastat (n. =. 13) using a within-subjects statistical analysis strategy. Specifically, the cardiovascular and subjective effects of cocaine were assessed in the presence of placebo (0. mg), 80. mg of nepicastat or 160. mg of nepicastat on study Days 4, 8 and 12, respectively. Analyses revealed a main effect of nepicastat to reduce several cocaine-induced positive subjective effects. Taken together, these data indicate that nepicastat is safe when co-administered with cocaine and may suppress its positive subjective effects, and may be viable as a pharmacotherapy for treatment of cocaine use disorder.

Original languageEnglish (US)
Pages (from-to)40-48
Number of pages9
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume59
DOIs
StatePublished - Jun 3 2015

Fingerprint

Mixed Function Oxygenases
Cocaine
Dopamine
nepicastat
Pharmacokinetics
Placebos
Inpatients
Safety
Drug Therapy

Keywords

  • Cocaine
  • Dopamine-β-hydroxylase
  • Nepicastat
  • SYN117

ASJC Scopus subject areas

  • Biological Psychiatry
  • Pharmacology

Cite this

Evaluation of the dopamine β-hydroxylase (DβH) inhibitor nepicastat in participants who meet criteria for cocaine use disorder. / De La Garza, Richard; Bubar, Marcy J.; Carbone, Crystal L.; Moeller, F. Gerard; Newton, Thomas F.; Anastasio, Noelle; Harper, Tod A.; Ware, David L.; Fuller, Michael; Holstein, Gaylyn J.; Jayroe, Jason B.; Bandak, Stephen I.; Reiman, Kirsten Z.; Neale, Ann C.; Pickford, Lesley B.; Cunningham, Kathryn.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 59, 03.06.2015, p. 40-48.

Research output: Contribution to journalArticle

De La Garza, R, Bubar, MJ, Carbone, CL, Moeller, FG, Newton, TF, Anastasio, N, Harper, TA, Ware, DL, Fuller, M, Holstein, GJ, Jayroe, JB, Bandak, SI, Reiman, KZ, Neale, AC, Pickford, LB & Cunningham, K 2015, 'Evaluation of the dopamine β-hydroxylase (DβH) inhibitor nepicastat in participants who meet criteria for cocaine use disorder', Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 59, pp. 40-48. https://doi.org/10.1016/j.pnpbp.2015.01.009
De La Garza, Richard ; Bubar, Marcy J. ; Carbone, Crystal L. ; Moeller, F. Gerard ; Newton, Thomas F. ; Anastasio, Noelle ; Harper, Tod A. ; Ware, David L. ; Fuller, Michael ; Holstein, Gaylyn J. ; Jayroe, Jason B. ; Bandak, Stephen I. ; Reiman, Kirsten Z. ; Neale, Ann C. ; Pickford, Lesley B. ; Cunningham, Kathryn. / Evaluation of the dopamine β-hydroxylase (DβH) inhibitor nepicastat in participants who meet criteria for cocaine use disorder. In: Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2015 ; Vol. 59. pp. 40-48.
@article{62816b82b17f47f28dbb210a20116bda,
title = "Evaluation of the dopamine β-hydroxylase (DβH) inhibitor nepicastat in participants who meet criteria for cocaine use disorder",
abstract = "In the present study, we tested the hypothesis that the potent and selective dopamine-β-hydroxylase (DβH) inhibitor nepicastat would have minimal effects on cardiovascular and pharmacokinetic parameters associated with cocaine administration and would reduce the positive subjective effects produced by cocaine. We conducted a double-blind, placebo-controlled, inpatient study of oral nepicastat (0, 80 and 160. mg) concurrent with intravenous (IV) cocaine (0, 10, 20 and 40. mg) in non-treatment seeking participants who metcriteria for cocaine use disorder. Safety analyses revealed that nepicastat was well-tolerated and there were no differences in adverse events observed after nepicastat plus cocaine vs. cocaine alone. In addition, the pharmacokinetic properties of cocaine administration were not altered by nepicastat treatment. Cocaine-induced cardiovascular and subjective effects were evaluated for completers in the cohort randomized to nepicastat (n. =. 13) using a within-subjects statistical analysis strategy. Specifically, the cardiovascular and subjective effects of cocaine were assessed in the presence of placebo (0. mg), 80. mg of nepicastat or 160. mg of nepicastat on study Days 4, 8 and 12, respectively. Analyses revealed a main effect of nepicastat to reduce several cocaine-induced positive subjective effects. Taken together, these data indicate that nepicastat is safe when co-administered with cocaine and may suppress its positive subjective effects, and may be viable as a pharmacotherapy for treatment of cocaine use disorder.",
keywords = "Cocaine, Dopamine-β-hydroxylase, Nepicastat, SYN117",
author = "{De La Garza}, Richard and Bubar, {Marcy J.} and Carbone, {Crystal L.} and Moeller, {F. Gerard} and Newton, {Thomas F.} and Noelle Anastasio and Harper, {Tod A.} and Ware, {David L.} and Michael Fuller and Holstein, {Gaylyn J.} and Jayroe, {Jason B.} and Bandak, {Stephen I.} and Reiman, {Kirsten Z.} and Neale, {Ann C.} and Pickford, {Lesley B.} and Kathryn Cunningham",
year = "2015",
month = "6",
day = "3",
doi = "10.1016/j.pnpbp.2015.01.009",
language = "English (US)",
volume = "59",
pages = "40--48",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Evaluation of the dopamine β-hydroxylase (DβH) inhibitor nepicastat in participants who meet criteria for cocaine use disorder

AU - De La Garza, Richard

AU - Bubar, Marcy J.

AU - Carbone, Crystal L.

AU - Moeller, F. Gerard

AU - Newton, Thomas F.

AU - Anastasio, Noelle

AU - Harper, Tod A.

AU - Ware, David L.

AU - Fuller, Michael

AU - Holstein, Gaylyn J.

AU - Jayroe, Jason B.

AU - Bandak, Stephen I.

AU - Reiman, Kirsten Z.

AU - Neale, Ann C.

AU - Pickford, Lesley B.

AU - Cunningham, Kathryn

PY - 2015/6/3

Y1 - 2015/6/3

N2 - In the present study, we tested the hypothesis that the potent and selective dopamine-β-hydroxylase (DβH) inhibitor nepicastat would have minimal effects on cardiovascular and pharmacokinetic parameters associated with cocaine administration and would reduce the positive subjective effects produced by cocaine. We conducted a double-blind, placebo-controlled, inpatient study of oral nepicastat (0, 80 and 160. mg) concurrent with intravenous (IV) cocaine (0, 10, 20 and 40. mg) in non-treatment seeking participants who metcriteria for cocaine use disorder. Safety analyses revealed that nepicastat was well-tolerated and there were no differences in adverse events observed after nepicastat plus cocaine vs. cocaine alone. In addition, the pharmacokinetic properties of cocaine administration were not altered by nepicastat treatment. Cocaine-induced cardiovascular and subjective effects were evaluated for completers in the cohort randomized to nepicastat (n. =. 13) using a within-subjects statistical analysis strategy. Specifically, the cardiovascular and subjective effects of cocaine were assessed in the presence of placebo (0. mg), 80. mg of nepicastat or 160. mg of nepicastat on study Days 4, 8 and 12, respectively. Analyses revealed a main effect of nepicastat to reduce several cocaine-induced positive subjective effects. Taken together, these data indicate that nepicastat is safe when co-administered with cocaine and may suppress its positive subjective effects, and may be viable as a pharmacotherapy for treatment of cocaine use disorder.

AB - In the present study, we tested the hypothesis that the potent and selective dopamine-β-hydroxylase (DβH) inhibitor nepicastat would have minimal effects on cardiovascular and pharmacokinetic parameters associated with cocaine administration and would reduce the positive subjective effects produced by cocaine. We conducted a double-blind, placebo-controlled, inpatient study of oral nepicastat (0, 80 and 160. mg) concurrent with intravenous (IV) cocaine (0, 10, 20 and 40. mg) in non-treatment seeking participants who metcriteria for cocaine use disorder. Safety analyses revealed that nepicastat was well-tolerated and there were no differences in adverse events observed after nepicastat plus cocaine vs. cocaine alone. In addition, the pharmacokinetic properties of cocaine administration were not altered by nepicastat treatment. Cocaine-induced cardiovascular and subjective effects were evaluated for completers in the cohort randomized to nepicastat (n. =. 13) using a within-subjects statistical analysis strategy. Specifically, the cardiovascular and subjective effects of cocaine were assessed in the presence of placebo (0. mg), 80. mg of nepicastat or 160. mg of nepicastat on study Days 4, 8 and 12, respectively. Analyses revealed a main effect of nepicastat to reduce several cocaine-induced positive subjective effects. Taken together, these data indicate that nepicastat is safe when co-administered with cocaine and may suppress its positive subjective effects, and may be viable as a pharmacotherapy for treatment of cocaine use disorder.

KW - Cocaine

KW - Dopamine-β-hydroxylase

KW - Nepicastat

KW - SYN117

UR - http://www.scopus.com/inward/record.url?scp=84921895050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921895050&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2015.01.009

DO - 10.1016/j.pnpbp.2015.01.009

M3 - Article

VL - 59

SP - 40

EP - 48

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

ER -